BGNE

BeiGeneNasdaqGS:BGNE Stock Report

Market Cap

US$35.8b

7D

14.2%

1Y

46.7%

Updated

16 Sep, 2021

Data

Company Financials +
BGNE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BGNE Overview

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People’s Republic of China and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for BeiGene
Historical stock prices
Current Share PriceUS$385.24
52 Week HighUS$219.20
52 Week LowUS$388.97
Beta0.88
1 Month Change36.84%
3 Month Change19.71%
1 Year Change46.69%
3 Year Change136.49%
5 Year Change1,135.54%
Change since IPO1,260.31%

Recent News & Updates

Shareholder Returns

BGNEUS BiotechsUS Market
7D14.2%-0.4%-0.6%
1Y46.7%25.7%33.6%

Return vs Industry: BGNE exceeded the US Biotechs industry which returned 24.9% over the past year.

Return vs Market: BGNE exceeded the US Market which returned 33.7% over the past year.

Price Volatility

Is BGNE's price volatile compared to industry and market?
BGNE volatility
BGNE Beta0.88
Industry Beta1.03
Market Beta1

Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: BGNE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20105,400John Oylerhttps://www.beigene.com

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People’s Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.

BeiGene Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
BGNE fundamental statistics
Market CapUS$35.84b
Earnings (TTM)-US$1.31b
Revenue (TTM)US$947.04m

37.8x

P/S Ratio

-27.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGNE income statement (TTM)
RevenueUS$947.04m
Cost of RevenueUS$1.41b
Gross Profit-US$458.98m
ExpensesUS$852.83m
Earnings-US$1.31b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-14.49
Gross Margin-48.46%
Net Profit Margin-138.52%
Debt/Equity Ratio17.5%

How did BGNE perform over the long term?

See historical performance and comparison

Valuation

Is BeiGene undervalued compared to its fair value and its price relative to the market?

46.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BGNE ($385.24) is trading below our estimate of fair value ($712.78)

Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BGNE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BGNE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BGNE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BGNE is overvalued based on its PB Ratio (9.9x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BGNE's revenue (25.8% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: BGNE's revenue (25.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BGNE is forecast to be unprofitable in 3 years.


Past Performance

How has BeiGene performed over the past 5 years?

-50.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BGNE is currently unprofitable.

Growing Profit Margin: BGNE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.

Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: BGNE has a negative Return on Equity (-36.41%), as it is currently unprofitable.


Financial Health

How is BeiGene's financial position?


Financial Position Analysis

Short Term Liabilities: BGNE's short term assets ($4.5B) exceed its short term liabilities ($706.6M).

Long Term Liabilities: BGNE's short term assets ($4.5B) exceed its long term liabilities ($1.2B).


Debt to Equity History and Analysis

Debt Level: BGNE's debt to equity ratio (17.5%) is considered satisfactory.

Reducing Debt: BGNE's debt to equity ratio has increased from 4.8% to 17.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BGNE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is BeiGene current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BGNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

John Oyler (53 yo)

11.67yrs

Tenure

US$14,409,330

Compensation

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD14.41M) is about average for companies of similar size in the US market ($USD11.33M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BGNE's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: BGNE's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BGNE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

BeiGene, Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: BeiGene, Ltd.
  • Ticker: BGNE
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$35.842b
  • Shares outstanding: 93.04m
  • Website: https://www.beigene.com

Number of Employees


Location

  • BeiGene, Ltd.
  • 94 Solaris Avenue
  • Camana Bay
  • Grand Cayman
  • Grand Cayman
  • KY1-1108
  • Cayman Islands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 22:55
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.